Summary of reduction in M-protein (a biomarker of efficacy; response-evaluable population)
| Patients, n (%) . | Mezagitamab cohort . | ||||||
|---|---|---|---|---|---|---|---|
| 45 mg (n = 4) . | 135 mg (n = 3) . | 300 mg (n = 12) . | 600 mg (n = 19) . | 1200 mg (n = 3) . | PomDex (n = 6) . | Total (N = 47) . | |
| Evaluable patients∗ | 1 (25) | 3 (100) | 10 (83) | 16 (84) | 2 (67) | 6 (100) | 38 (81) |
| 100% reduction | 0 | 0 | 2 (20) | 1 (6) | 0 | 0 | 3 (8) |
| 75% to <90% reduction | 0 | 0 | 0 | 3 (19) | 0 | 3 (50) | 6 (16) |
| 50% to <75% reduction | 0 | 0 | 2 (20) | 4 (25) | 0 | 2 (33) | 8 (21) |
| ≥50% reduction | 0 | 0 | 4 (40) | 8 (50) | 1 (50) | 5 (83) | 18 (47) |
| Patients, n (%) . | Mezagitamab cohort . | ||||||
|---|---|---|---|---|---|---|---|
| 45 mg (n = 4) . | 135 mg (n = 3) . | 300 mg (n = 12) . | 600 mg (n = 19) . | 1200 mg (n = 3) . | PomDex (n = 6) . | Total (N = 47) . | |
| Evaluable patients∗ | 1 (25) | 3 (100) | 10 (83) | 16 (84) | 2 (67) | 6 (100) | 38 (81) |
| 100% reduction | 0 | 0 | 2 (20) | 1 (6) | 0 | 0 | 3 (8) |
| 75% to <90% reduction | 0 | 0 | 0 | 3 (19) | 0 | 3 (50) | 6 (16) |
| 50% to <75% reduction | 0 | 0 | 2 (20) | 4 (25) | 0 | 2 (33) | 8 (21) |
| ≥50% reduction | 0 | 0 | 4 (40) | 8 (50) | 1 (50) | 5 (83) | 18 (47) |
PomDex was given in combination with mezagitamab 300 mg (administered per the product label).
Patients with measurable serum M-protein at baseline and at least 1 postbaseline M-protein assessment.